Parnaparin Sodium

Summary

Parnaparin Sodium (CHEMBL2108080) is a phase-3 clinical-stage oligosaccharide; indicated across 2 conditions including infertility disorder and thrombophlebitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108080
Name	Parnaparin Sodium
Type	Oligosaccharide
Max phase	3

Also known as: Fluxum, Lowepa, Minidalton, OP-2123, Parnaparin sodium, Parnaparina de sodio, Parnaparine sodique, Tromboparin, PARNAPARIN SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545
thrombophlebitis	3	MONDO:0002800	HP:0004418

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02991950	PHASE3	TERMINATED	Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).